嚢胞性線維症（CF）治療薬の世界市場レポート 2024年

嚢胞性線維症（CF）治療薬の市場規模は近年急速に拡大しています。2023年の69億1,000万米ドルから2024年には76億3,000万米ドルへと、CAGR10.4％で拡大します。過去数年間に見られた成長は、標的治療の進歩、嚢胞性線維症（CF）の遺伝学的理解の深まり、患者擁護と認知度の向上、研究イニシアティブに対する政府の支援、希少疾病研究に対する優遇措置（希少疾病用医薬品の指定など）など、いくつかの要因によるものです。これらの要素が複合的に、過去一定期間における嚢胞性線維症の治療薬の進歩と発展に寄与しました。

2023年の嚢胞性線維症（CF）治療薬市場では、北米が最大の地域でした。アジア太平洋は、予測期間中に嚢胞性線維症（CF）治療薬市場で最も急成長する地域と予想されます。嚢胞性線維症（CF）治療薬市場レポートの対象地域は、アジア太平洋,西欧,東欧,北米,南米,中東,アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 嚢胞性線維症（CF）治療薬市場の特徴

第3章 嚢胞性線維症（CF）治療薬市場の動向と戦略

第4章 嚢胞性線維症（CF）治療薬市場- マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の嚢胞性線維症（CF）治療薬市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 嚢胞性線維症（CF）治療薬市場セグメンテーション

• 世界の嚢胞性線維症（CF）治療薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 膵臓酵素サプリメント
• 粘液溶解性
• 気管支拡張薬
• CFTR変調器
• 世界の嚢胞性線維症（CF）治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• オーラル
• 吸入した
• 世界の嚢胞性線維症（CF）治療薬市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 薬剤
• デバイス

第7章 嚢胞性線維症（CF）治療薬市場の地域および国分析

• 世界の嚢胞性線維症（CF）治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の嚢胞性線維症（CF）治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋の嚢胞性線維症（CF）治療薬市場

第9章 中国の嚢胞性線維症（CF）治療薬市場

第10章 インドの嚢胞性線維症（CF）治療薬市場

第11章 日本の嚢胞性線維症（CF）治療薬市場

第12章 オーストラリアの嚢胞性線維症（CF）治療薬市場

第13章 インドネシアの嚢胞性線維症（CF）治療薬市場

第14章 韓国の嚢胞性線維症（CF）治療薬市場

第15章 西欧の嚢胞性線維症（CF）治療薬市場

第16章 英国の嚢胞性線維症（CF）治療薬市場

第17章 ドイツの嚢胞性線維症（CF）治療薬市場

第18章 フランスの嚢胞性線維症（CF）治療薬市場

第19章 イタリアの嚢胞性線維症（CF）治療薬市場

第20章 スペインの嚢胞性線維症（CF）治療薬市場

第21章 東欧の嚢胞性線維症（CF）治療薬市場

第22章 ロシアの嚢胞性線維症（CF）治療薬市場

第23章 北米の嚢胞性線維症（CF）治療薬市場

第24章 米国の嚢胞性線維症（CF）治療薬市場

第25章 カナダの嚢胞性線維症（CF）治療薬市場

第26章 南米の嚢胞性線維症（CF）治療薬市場

第27章 ブラジルの嚢胞性線維症（CF）治療薬市場

第28章 中東の嚢胞性線維症（CF）治療薬市場

第29章 アフリカの嚢胞性線維症（CF）治療薬市場

第30章 嚢胞性線維症（CF）治療薬市場の競合情勢と企業プロファイル

• 嚢胞性線維症（CF）治療薬市場の競合情勢
• 嚢胞性線維症（CF）治療薬市場の企業プロファイル
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche AG
  • Vertex Pharmaceuticals Incorporated
  • Chiesi Farmaceutici SpA
  • PTC Therapeutics LIMITED

第31章 世界の嚢胞性線維症（CF）治療薬市場の競合ベンチマーキング

第32章 世界の嚢胞性線維症（CF）治療薬市場の競争ダッシュボード

第33章 嚢胞性線維症（CF）治療薬市場における主要な合併と買収

第34章 嚢胞性線維症（CF）治療薬市場の将来展望と可能性分析

第35章 付録

“Cystic Fibrosis (CF) Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cystic fibrosis (cf) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cystic fibrosis (cf) therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The cystic fibrosis (cf) therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug Class: Pancreatic Enzyme Supplements; Mucolytic; Bronchodilators; CFTR Modulators
• 2) By Route Of Administration: Oral; Inhaled
• 3) By Treatment Method: Medication; Devices
• Companies Mentioned: Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche AG; Vertex Pharmaceuticals Incorporated; Chiesi Farmaceutici SpA; PTC Therapeutics LIMITED
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Cystic fibrosis (CF) therapeutics encompasses medications designed to thin and facilitate the coughing up of lung mucus in individuals with this inherited disorder. CF causes severe damage to the lungs, digestive system, and other organs.

The primary drug classes for CF therapeutics include pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators. Pancreatic enzyme supplements contain pancreatin or pancrelipase, a combination of lipase, amylase, and protease, produced by the pancreas. These supplements can be administered orally or through inhalation. The treatment methods for cystic fibrosis involve a combination of medications and devices to manage the condition effectively.

The cystic fibrosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides cystic fibrosis therapeutics market statistics, including cystic fibrosis therapeutics industry global market size, regional shares, competitors with a cystic fibrosis therapeutics market share, detailed cystic fibrosis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the cystic fibrosis therapeutics industry. This cystic fibrosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cystic fibrosis (cf) therapeutics market size has grown rapidly in recent years. It will grow from $6.91 billion in 2023 to $7.63 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth observed in the historic period can be attributed to several factors, including advancements in targeted therapies, a deeper understanding of cystic fibrosis (CF) genetics, increased patient advocacy and awareness, government support for research initiatives, and incentives for rare disease research, such as orphan drug designations. These elements collectively contributed to the progress and development of therapeutics for cystic fibrosis during the historical period.

The cystic fibrosis (cf) therapeutics market size is expected to see strong growth in the next few years. It will grow to $10.59 billion in 2028 at a compound annual growth rate (CAGR) of 8.6%. The anticipated growth in the forecast period can be attributed to factors such as the rise in the cystic fibrosis (CF) patient population, regulatory approvals for novel therapies, a focus on personalized medicine, increased investment in biomarker research, expanded newborn screening programs, and healthcare policy support. Major trends expected in the forecast period include the expansion of CFTR modulators, the utilization of gene editing technologies, early intervention strategies, improved diagnostic techniques, the integration of telehealth and remote monitoring, the digitalization of healthcare, and advancements in chronic disease management.

The projected increase in the population affected by cystic fibrosis (CF) is set to be a driving force behind the expansion of the cystic fibrosis therapeutics market. CF, an inherited condition impacting the lungs, digestive system, and other organs, necessitates therapeutic interventions to thin lung mucus, making it easier to expel. As the number of individuals suffering from cystic fibrosis rises, the demand for effective CF therapeutics is expected to soar. An illustrative example is a report released by The Cystic Fibrosis (CF) Foundation in July 2022, revealing a surge in CF cases, with almost 40,000 affected individuals in the United States and over 105,000 diagnosed worldwide. This escalation in CF patients is a significant driving factor fueling the cystic fibrosis therapeutics market growth.

The burgeoning emphasis on personalized medicine and targeted therapies is poised to drive the cystic fibrosis therapeutics market forward. Personalized medicine involves tailoring medical care based on patients' unique genetic makeup, proteins, and other biological factors, enabling precise and individualized treatments. This approach aids in comprehending the intricate genetic mutations underlying CF, paving the way for customized treatment plans aligned with each patient's distinct genetic profile. Notably, The Scope and Significance of Progress in 2022 report by the Personalized Medicine Coalition highlighted the US Food and Drug Administration's approval of 12 personalized medicines in 2022, constituting approximately 34% of all newly approved therapeutic molecular entities. This growing focus on personalized medicine and targeted therapies is a driving force behind the expansion of the cystic fibrosis therapeutics market.

Product innovation stands out as a pivotal trend gaining traction within the cystic fibrosis therapeutics market. Leading companies in this sector are dedicating efforts to developing novel products to gain a competitive edge. For instance, Chiesi USA introduced Bronchitol (mannitol) powder in March 2021-a groundbreaking inhalation powder designed for cystic fibrosis patients. Distinguished as the 'First and Only' dry-powder inhaled mucoactive agent, Bronchitol offers unique features such as portability, no refrigeration requirement, and reduced cleaning frequency, setting a new standard for convenience and efficacy in CF therapeutic interventions. This product innovation signifies a growing trend towards more accessible and effective treatments within the cystic fibrosis therapeutics market.

Key players within the cystic fibrosis (CF) therapeutics market are actively directing their efforts towards strategic investments aimed at expanding their presence and fortifying their market positions. Strategic investment in medical research encompasses a deliberate allocation of resources, expertise, and funding into scientific research endeavors with the primary objectives of advancing medical understanding, developing innovative treatments, and refining healthcare protocols. An exemplary instance of such strategic investment occurred in January 2023 when the Cystic Fibrosis Foundation (CF Foundation), a US-based non-profit organization dedicated to supporting diverse research initiatives for CF cure, announced a significant investment of up to $15 million in ReCode Therapeutics. ReCode, a US-based clinical-stage genetic medicines and biotechnology company, specializes in employing advanced delivery mechanisms to drive the next wave of messenger ribonucleic acid (mRNA) and gene correction therapeutics. This substantial investment is intended to facilitate the development of ReCode's inhaled mRNA-based therapeutic tailored for individuals with cystic fibrosis (CF), particularly those with genotypes unresponsive to approved cystic fibrosis transmembrane conductance regulator (CFTR) modulators.

In November 2021, the CF Foundation embarked on a collaborative effort with Flagship Pioneering, a US-based life sciences venture capital company, under the Pioneering Medicines initiative to propel the advancement of genetically based treatments for cystic fibrosis. This partnership, part of the Foundation's Path to a Cure research agenda, entails a planned investment of up to $110 million, with an initial commitment of $20 million. The Pioneering Medicines initiative will amalgamate technologies from various flagship-founded enterprises to establish a distinct entity dedicated to exploring novel approaches to treating cystic fibrosis. These strategic investments underscore the commitment of major stakeholders in the cystic fibrosis therapeutics market to foster innovation, drive research, and pioneer new treatments for individuals affected by this condition.

Major companies operating in the cystic fibrosis (cf) therapeutics market report are Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Vertex Pharmaceuticals Incorporated, Chiesi Farmaceutici SpA, PTC Therapeutics LIMITED, Genentech Inc., Alaxia, AstraZeneca, Beyond Air Inc., Pfizer Inc., Alcresta Therapeutics Inc., Laurent Pharmaceuticals, Nestle HealthScience, Vivus, Pharmaxis, Genentech, Bayer AG, Eli Lilly and Company, AbbVie Inc., Novartis AG, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc, ProQR Therapeutics N.V., Enterprise Therapeutics Ltd. , Corbus Pharmaceuticals Holdings Inc, Eloxx Pharmaceuticals , Translate Bio Inc, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc. , Zambon S.p.A .

North America was the largest region in the cystic fibrosis (CF) therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the cystic fibrosis (CF) therapeutics market during the forecast period. The regions covered in the cystic fibrosis (cf) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cystic fibrosis (cf) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cystic fibrosis (CF) therapeutics market includes revenues earned by entities by providing services that include administration of mucus thinner, airway clearance, and antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Cystic Fibrosis (CF) Therapeutics Market Characteristics

3. Cystic Fibrosis (CF) Therapeutics Market Trends And Strategies

4. Cystic Fibrosis (CF) Therapeutics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Cystic Fibrosis (CF) Therapeutics Market Size and Growth

• 5.1. Global Cystic Fibrosis (CF) Therapeutics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Cystic Fibrosis (CF) Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Cystic Fibrosis (CF) Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cystic Fibrosis (CF) Therapeutics Market Segmentation

• 6.1. Global Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Pancreatic Enzyme Supplements
• Mucolytic
• Bronchodilators
• CFTR Modulators
• 6.2. Global Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Inhaled
• 6.3. Global Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Medication
• Devices

7. Cystic Fibrosis (CF) Therapeutics Market Regional And Country Analysis

• 7.1. Global Cystic Fibrosis (CF) Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Cystic Fibrosis (CF) Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market

• 8.1. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cystic Fibrosis (CF) Therapeutics Market

• 9.1. China Cystic Fibrosis (CF) Therapeutics Market Overview
• 9.2. China Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cystic Fibrosis (CF) Therapeutics Market

• 10.1. India Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cystic Fibrosis (CF) Therapeutics Market

• 11.1. Japan Cystic Fibrosis (CF) Therapeutics Market Overview
• 11.2. Japan Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cystic Fibrosis (CF) Therapeutics Market

• 12.1. Australia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cystic Fibrosis (CF) Therapeutics Market

• 13.1. Indonesia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cystic Fibrosis (CF) Therapeutics Market

• 14.1. South Korea Cystic Fibrosis (CF) Therapeutics Market Overview
• 14.2. South Korea Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cystic Fibrosis (CF) Therapeutics Market

• 15.1. Western Europe Cystic Fibrosis (CF) Therapeutics Market Overview
• 15.2. Western Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cystic Fibrosis (CF) Therapeutics Market

• 16.1. UK Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cystic Fibrosis (CF) Therapeutics Market

• 17.1. Germany Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cystic Fibrosis (CF) Therapeutics Market

• 18.1. France Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cystic Fibrosis (CF) Therapeutics Market

• 19.1. Italy Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cystic Fibrosis (CF) Therapeutics Market

• 20.1. Spain Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cystic Fibrosis (CF) Therapeutics Market

• 21.1. Eastern Europe Cystic Fibrosis (CF) Therapeutics Market Overview
• 21.2. Eastern Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cystic Fibrosis (CF) Therapeutics Market

• 22.1. Russia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cystic Fibrosis (CF) Therapeutics Market

• 23.1. North America Cystic Fibrosis (CF) Therapeutics Market Overview
• 23.2. North America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cystic Fibrosis (CF) Therapeutics Market

• 24.1. USA Cystic Fibrosis (CF) Therapeutics Market Overview
• 24.2. USA Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cystic Fibrosis (CF) Therapeutics Market

• 25.1. Canada Cystic Fibrosis (CF) Therapeutics Market Overview
• 25.2. Canada Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cystic Fibrosis (CF) Therapeutics Market

• 26.1. South America Cystic Fibrosis (CF) Therapeutics Market Overview
• 26.2. South America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cystic Fibrosis (CF) Therapeutics Market

• 27.1. Brazil Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cystic Fibrosis (CF) Therapeutics Market

• 28.1. Middle East Cystic Fibrosis (CF) Therapeutics Market Overview
• 28.2. Middle East Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cystic Fibrosis (CF) Therapeutics Market

• 29.1. Africa Cystic Fibrosis (CF) Therapeutics Market Overview
• 29.2. Africa Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Cystic Fibrosis (CF) Therapeutics Market, Segmentation By Treatment Method, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cystic Fibrosis (CF) Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Cystic Fibrosis (CF) Therapeutics Market Competitive Landscape
• 30.2. Cystic Fibrosis (CF) Therapeutics Market Company Profiles
  • 30.2.1. Teva Pharmaceutical Industries Ltd.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Vertex Pharmaceuticals Incorporated
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Chiesi Farmaceutici SpA
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. PTC Therapeutics LIMITED
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Cystic Fibrosis (CF) Therapeutics Market Competitive Benchmarking

32. Global Cystic Fibrosis (CF) Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Cystic Fibrosis (CF) Therapeutics Market

34. Cystic Fibrosis (CF) Therapeutics Market Future Outlook and Potential Analysis

• 34.1 Cystic Fibrosis (CF) Therapeutics Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Cystic Fibrosis (CF) Therapeutics Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Cystic Fibrosis (CF) Therapeutics Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer